BCAL Diagnostics Limited ABN 51 142 051 223 Suite 506 Level 5 50 Clarence Street Sydney NSW 2000 T +61 407 983 270 W www.bcaldiagnostics.com E [email protected] 17 September 2026 ANNUAL GENERAL MEETING NOTICE AND PROXY FORM Dear Shareholder, The Annual General Meeting (Meeting) of...
Letter to Shareholders re Annual General Meeting
Filed with ASX · · 1 page · English
Release
BCAL Diagnostics Limited on 6ix
Story so far
Earlier from BCAL Diagnostics
- Notice of Annual General Meeting/Proxy Form
- Clarification of BCAL's Position in Relation to GSS
- BCAL Seeks Board Change at Genetic Signatures
- Investor Presentation September 2026
- Meet The CEO FY 2026 Results Webinar 3 Sept 2026 at 1PM
Later from BCAL Diagnostics
- BCAL Introduces Avantect Multi-Cancer Early Detection Test
- BREASTESTplus 2 clinically validated
- Change in substantial holding
- Investor Presentation - Transforming Cancer Detection
- Letter to Genetic Signatures Ltd Shareholders
Follow BCAL Diagnostics into a list and get an email when it puts out news.
Follow BCAL Diagnostics